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Background/introduction
High-Intensity Focused Ultrasound (HIFU) is a promis-
ing non-invasive treatment for localized solid tumors.
While patients treated with HIFU show symptomatic
improvement, the majority die from local recurrence
and metastases due to incomplete tumor ablation and
inability to control spread outside the primary tumor
site. Therefore, improved local control and a concomi-
tant systemic therapeutic effect would be valuable for
successful tumor control by HIFU. Low intensity
focused ultrasound (LOFU) induces sonic stress by rais-
ing the temperature without killing the cells. We
demonstrated that tumor pre-treatment with LOFU
prior to HIFU results in tumor growth retardation
(Figure 1A) and induces a Th1 predominant immune
response (Figure 1B). To further validate the immunolo-
gical consequences of LOFU pre-treatment, we investi-
gated the immunomodulation of prostate cancer caused
by LOFU. We previously demonstrated that LOFU
induced expression of genes related to the unfolded pro-
tein response (UPR) and endoplasmic reticulum (ER)
stress. We hypothesize that LOFU increases immuno-
modulatory surface signals, such as heat shock protein
70 (HSP70) and calreticulin. HSP70 is an endogenous
“danger” signal, which can activate dendritic cells. Calre-
ticulin is an “eat me” signal, which encourages phagocy-
tosis and thus antigen processing for presentation on
cell surface MHC for T cell recognition. Thus, sequen-
tial administration of LOFU and HIFU provides a source
of tumor antigens and endogenous “danger” signals for
dendritic cell (DC) activation, thereby inducing a tumor-
specific systemic immune response that augments the
efficacy of therapeutic ultrasound to control both local
and systemic disease.
Methods
LOFU treatment was performed on the Philips Therapy
and Imaging Probe System (TIPS, Philips Research
Briarcliff, USA) using 3W, 100% duty cycle, 1.5 seconds,
1 mm spacing. For IF analysis, LOFU-treated cells were
cytospined and fixed with 4% paraformaldehyde and
stained with rabbit ant-HSP70 overnight, followed by
incubation with a secondary goat anti-rabbit PE conju-
gated and anti-phalloidin antibodies for 1 hour at room
temperature. DAPI was included in the mounting med-
ium and slides were analyzed using an Inverted Olym-
pus IX81. Flow cytometry staining included a live/dead
cell marker to isolate only living cells expressing HSP70
on the cell surface.
Results and conclusions
The immunomodulatory effect of LOFU was analyzed on
prostate cancer cell lines, both human and murine, by
detecting the surface expression of HSP70 and calreticulin
by flow cytometry & immunofluorescence (IF) six hours
following LOFU treatment of a cell pellet. LOFU signifi-
cantly induced cell surface HSP70 expression and calreti-
culin in vitro in human and mouse prostate cancer cell
lines, as shown by flow cytometry (Figure 1C) and con-
firmed by IF (Figure 1D). Surface HSP70 is a danger signal
which can activate dendritic cells to induce an anti-tumor
immune response. Surface calreticulin acts as a “eat me”
signal for phagocytic cells, resulting in increased phagocy-
tosis and antigen processing. Immunomodulation by
LOFU can attract DCs to the tumor and induce a Th1
predominant immune response.
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Figure 1 A. Tumor Growth Retardation. B. LOFU+HIFU induced tumor-specific T cell response. C. Flow cytometry of HSP70 and calreticulin of
LOFU-treated prostate cancer cells. D. IF of RM-1 and PC3 cells stained for HSP70
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